Clonidine

Limits on what this shows

• Key negative / null findings: None of the three mitochondrial fractions in Villa 2022 showed uniform decline; the free-mitochondria fraction showed net increases across all three enzymes measured, which argues against a simple, uniform mitochondrial toxicity story at this dose.
• At-risk subgroups: None defined. The single dose used (5 µg/kg intraperitoneal, acute) does not map cleanly onto sustained oral human therapy, and no repeat-dose or chronic mitochondrial study in any species was located.

Regulatory status

Mitochondria and mitochondrial function are not named anywhere in the clonidine prescribing information reviewed for this dossier (DailyMed clonidine ER and Catapres labels; Health Canada monograph).

Population evidence

None in humans. Tier B with clonidine in the cohort: Villa, Gorini and Ferrari, Neurochem Res 2022;47(5):1429-1441 (doi 10.1007/s11064-022-03541-z, PMID 35099720): 3-month-old male Sprague-Dawley rats, a single acute dose of clonidine 5 µg/kg intraperitoneally, sacrificed 30 minutes later; catalytic activity of citrate synthase, cytochrome oxidase, glutamate-oxaloacetate transaminase and glutamate dehydrogenase was measured across three separated mitochondrial subpopulations of temporal cerebral cortex (free, light and heavy mitochondria, corresponding to different synaptic compartments). In free mitochondria, citrate synthase, cytochrome oxidase and the transaminase all rose. In light mitochondria, citrate synthase fell while cytochrome oxidase and the transaminase rose. In heavy mitochondria, citrate synthase, cytochrome oxidase and glutamate dehydrogenase all fell. Two further Tier B sources with clonidine in the cohort were located but their full text could not be independently retrieved for this review after repeated attempts (see Sources): an in vitro study reporting clonidine-induced, mitochondria-dependent apoptotic signaling in human corneal epithelial cells, and a 1989 rat hippocampal study comparing piracetam and clonidine across different mitochondrial populations. Neither is load-bearing for this entry; both are named to document their existence and general subject matter only, with no statistic drawn from either.

Mechanism

Plausible but not resolved in either direction. Clonidine's central action, reduced presynaptic norepinephrine release via alpha-2 autoreceptors, plausibly changes energy demand differently in presynaptic versus postsynaptic mitochondrial compartments, which is the authors' own explanation for the compartment-specific pattern. There is no described route by which clonidine would impair oxidative phosphorylation generally: it is not metabolized to a reactive intermediate by any named enzyme, and roughly half of an absorbed dose is cleared unchanged by the kidney.

Counter-evidence held on record

The same study is its own partial counter-evidence: net enzyme activity rose rather than fell in the free-mitochondria fraction, the compartment closest to a general marker of tissue mitochondrial content. Nothing in the label or in any clonidine pharmacokinetic source reviewed describes a route to mitochondrial injury, since the drug is not extensively metabolized and generates no reactive intermediate at either tier of evidence located. Do not say clonidine damages or protects mitochondria; neither is established in humans, and the one detailed animal study found opposite effects in different parts of the same tissue. Fatigue or sedation reported on clonidine has a label-documented explanation, central alpha-2 agonism itself, and should not be attributed to mitochondrial dysfunction. No coenzyme Q10, carnitine, ribose or other mitochondrial supplement recommendation follows from this entry, and none is made.

Limits on what this shows

• Key negative / null findings: None of the protective-direction studies report a null or contradicting result within their own design; the tension in this entry is between studies, not within any one of them. No study locates a dose-response relationship spanning both directions in the same protocol, so it cannot be said at what exposure, if any, clonidine shifts from net protective to net damaging in a given tissue.
• At-risk subgroups: None defined by clonidine-specific human data, because none exists.
• Dose and duration: The SHR, hemorrhagic-shock and hypoxic-stress studies used clonidine as a pretreatment or ongoing treatment described in the original reports as antihypertensive-range for the species; the two "clonidine-induced" model papers used clonidine as the inciting agent, which strongly implies a higher, model-generating dose, though the exact figure could not be confirmed from the material retrieved for this review.

Regulatory status

Oxidative stress, antioxidant enzymes and reactive oxygen species are not named anywhere in the clonidine prescribing information.

Population evidence

None in humans. Tier B with clonidine in the cohort, protective direction: Nik Yusoff, Mustapha, Govindasamy and Sirajudeen, Oxid Med Cell Longev 2013 (PMID 23766863, full abstract retrieved): spontaneously hypertensive rats given clonidine; total antioxidant status (TAS) rose and thiobarbituric acid reactive substances (TBARS, a lipid peroxidation marker) fell in heart tissue, both p < 0.001. Filos et al., Redox Rep 2012 (PMID 23339860, full text not independently retrieved after repeated attempts, title and search-listing snippet only): clonidine pretreatment prevented hemorrhagic-shock-induced endotoxemia and oxidative stress in rat gut, liver and lung. Adebayo et al., Naunyn Schmiedebergs Arch Pharmacol 2026 (PMID 41351793, full text not independently retrieved): clonidine attenuated chronic-hypoxic-stress-induced behavioral abnormalities in mice through suppression of oxidative stress and pro-inflammatory cytokines. Tier B with clonidine in the cohort, damaging direction: El-Naga, Ahmed and Abd Al Haleem, Neurotoxicology 2014 (PMID 24877722, full text not independently retrieved): a rat model the authors describe as "clonidine-induced neurotoxicity," with oxidative stress, inflammation, apoptosis and monoamine levels as endpoints, testing indole-3-carbinol as a protective agent against it. Abd Al Haleem, Ahmed and El-Naga, J Diet Suppl 2023 (PMID 34633271, full text not independently retrieved): a rat model described as "clonidine-induced depression-like behavior," testing lycopene and chrysin against neuroinflammation and oxidative stress in that model. The dose of clonidine used to produce these two experimental models could not be confirmed from the material retrieved and is very unlikely to reflect therapeutic human dosing; both papers come from overlapping authorship using clonidine as a pharmacological tool to produce a pathological phenotype, not as the object of a safety study.

Mechanism

Plausible in both directions and not resolved. Clonidine suppresses central and peripheral norepinephrine release, and catecholamines auto-oxidize to generate reactive intermediates, which gives a plausible route to a protective, lower-oxidative-burden effect at doses that reduce sympathetic tone, consistent with the SHR, hemorrhagic-shock and hypoxic-stress findings above. Separately, clonidine is a ligand at imidazoline receptors situated on the outer mitochondrial membrane in proximity to monoamine oxidase, an enzyme that generates hydrogen peroxide as a normal byproduct of its catalytic cycle; at high enough exposure this offers a plausible, distinct route to increased oxidative burden, though no study located measured monoamine oxidase activity or hydrogen peroxide output directly in a clonidine-treated system.

Counter-evidence held on record

The protective-direction and damaging-direction findings are each other's counter-evidence, and both are printed rather than one being suppressed in favor of the other. No human oxidative stress marker, glutathione, selenium, or lipid peroxidation panel has ever been reported for a clonidine-treated patient, so neither direction can be extended to people on the basis of what is here. Do not state that clonidine causes oxidative stress, and do not state that it is protective against it; both directions exist only in animals, at doses not shown to match human therapy, and the "clonidine-induced" model papers used the drug specifically to create damage, which says little about standard clinical dosing. No selenium, glutathione or antioxidant supplement recommendation follows from this entry.

Limits on what this shows

• Key negative / null findings: No study located reports a null result for clonidine and copper status, because no study located measured copper status on clonidine at all. This is an evidence gap around the enzyme-inhibition finding, not a contradiction of it.
• At-risk subgroups: None definable. There is no clonidine copper-status dataset from which to identify one.

Regulatory status

Copper is not named anywhere in the clonidine prescribing information.

Population evidence

None at any tier for copper status. Tier B in vitro enzyme kinetics with clonidine in the cohort: a study of competitive inhibition of swine kidney copper amine oxidase by amiloride, clonidine and gabexate mesylate ( Biochem Biophys Res Commun 1997, PMID 9367901, full text not independently retrieved beyond the title and a search-listing snippet), and a companion study of competitive inhibition of Lens culinaris (lentil) copper amine oxidase by amiloride, p-aminobenzamidine, clonidine and related compounds ( J Enzyme Inhib 1998, PMID 9825309, full text not independently retrieved). Both describe clonidine acting as a competitive inhibitor at the enzyme's active site. A third Tier B animal source, testing clonidine and idazoxan against tetrathiomolybdate-induced copper and lysosomal enzyme excretion into sheep bile in copper-loaded and copper-replete sheep ( Res Vet Sci 2012, PMID 21570700, full text not independently retrieved), is named to document its existence and general subject matter; no statistic or direction of effect is cited from it here because the full text could not be confirmed after repeated attempts.

Mechanism

Present and specific, but it is enzyme-inhibition chemistry, not a copper-status mechanism. Copper amine oxidases are genuine copper metalloenzymes that break down biogenic amines; clonidine's competitive inhibition of this enzyme family is analogous in kind, though not in target, to zinc-metalloenzyme chemistry documented for other antihypertensive classes elsewhere in this dossier series. Nothing in this chemistry implies clonidine changes how much copper a person absorbs, stores or excretes; it implies clonidine can compete with copper amine oxidase's normal substrate at the enzyme's active site in vitro.

Counter-evidence held on record

None specific to clonidine and copper status exists to counter, which is itself the limiting fact on this entry: the enzyme-inhibition chemistry is real but isolated, with no in vivo copper measurement on either side of it. Do not state or imply that clonidine depletes copper. The accurate framing is that clonidine interacts with one class of copper-containing enzyme in a test tube, and that copper status itself has never been measured on this drug in any species. No copper testing and no copper supplement is recommended by this dossier.

Limits on what this shows

• Why no grade: Yellow requires either mechanistic plausibility demonstrated at Tier B or class extrapolation at Tier C where at least one class member has real supporting data for the effect in question. Neither condition is met: no alpha-2 agonist or imidazoline-receptor ligand has been shown to alter iron status, and no clonidine-specific iron finding exists at any tier. White requires a circulating claim to rebut; the consumer nutrient-depletion sources already reviewed for this dossier's original claim audit (the Pelton handbook and its re-syndications, the LivOn Labs and Life Extension articles, and the U.S. Pharmacist continuing-education review) name clonidine only in connection with coenzyme Q10, and make no iron claim for this drug. The category therefore sits outside all four tiers.
• The confounding-by-indication risk, addressed directly: Restless legs syndrome is strongly and repeatedly associated in the literature with brain iron deficiency (for example Trenkwalder et al., Lancet Neurol 2018, PMID 30244828, and several further reviews located in the same search), and clonidine is sometimes used off-label as an alpha-2 agonist for restless legs symptoms when first-line therapy is inadequate. A reader could reasonably but wrongly infer from "clonidine is used for restless legs, and restless legs is caused by iron deficiency" that clonidine itself depletes iron. It does not: the iron deficiency in restless legs syndrome is the condition being treated, present before clonidine is ever prescribed, and no study locates clonidine as a cause or a corrector of that deficiency. This is filed here explicitly so the inference is not left for a reader to draw unaided.
• What would fill it: A study directly measuring serum iron, ferritin, transferrin saturation or hepcidin in a defined clonidine-treated human or animal cohort, ideally against an untreated comparator, with clonidine named as a study arm rather than pooled into "alpha-2 agonists" or "antihypertensives."

What was searched

PubMed, September 10, 2026, clonidine combined with iron, ferritin, and restless legs syndrome. The iron- and ferritin-specific terms returned no clonidine-specific status study. The restless-legs search returned nine results, all general reviews of restless legs syndrome pathophysiology and treatment; none measured iron status in a clonidine-treated cohort.

Counter-evidence held on record

There is none to hold, which is the finding. Nothing supports an iron-depletion claim for clonidine and nothing rules one out. Absence of evidence is not evidence of safety. Do not publish "clonidine does not affect iron status," which the literature does not support, and do not publish an iron-testing or iron-supplement prompt attached to this drug either. If restless legs syndrome comes up in connection with clonidine, the accurate framing is that iron deficiency is a cause of the syndrome being treated, not a consequence of the drug.

Limits on what this shows

• Key negative / null findings: Zhao 2023 did not report whether the clonidine-treated group's diversity was fully restored to the level of the unstressed control group or only partially restored relative to the untreated stressed group; that specific comparison could not be confirmed from the material retrieved. No study has tested whether clonidine's constipating effect independently shifts microbiota composition in either humans or animals under normal, unstressed conditions, so the competing mechanism above remains untested rather than contradicted.
• At-risk subgroups: None defined by clonidine-specific human data. The one animal finding is specific to a circadian-disruption stress model and should not be generalized to routine clonidine use in an otherwise unstressed patient.
• Confounding check: Per this dossier's standing rule on confounding by indication, the Zhao 2023 model is itself a stress-and-rescue design: the disturbance being corrected is caused by the continuous-light stressor, and clonidine's role is to blunt the sympathetic overactivation that stressor produces, not to act on the gut microbiome directly. This is a downstream, physiology-mediated effect, not a direct drug-microbiome interaction, and is described as such.

Regulatory status

Gut microbiome, microbiota and intestinal flora are not named anywhere in the clonidine prescribing information. Constipation is listed at approximately 10 in 100 patients in the Catapres label's adverse reaction tables, and colonic pseudo-obstruction is separately listed among gastrointestinal adverse reactions.

Population evidence

None in humans. One Tier B animal source with clonidine directly in the cohort: Zhao, Ma, Ren et al., Heliyon 2023;10(1):e22742 (doi 10.1016/j.heliyon.2023.e22742, PMID 38192835, PMCID PMC10772574, full abstract retrieved). Male rats over 14 weeks in three groups: normal light control, continuous light exposure alone, and continuous light exposure plus clonidine hydrochloride. Blood pressure, heart rate and body weight were all significantly higher in the untreated continuous-light group than in either the control or the clonidine-treated group (p < 0.05). Gut microbial Shannon diversity index was significantly higher in the clonidine-treated group than in the untreated continuous-light group (p = 0.012), and beta diversity differed significantly between groups (p = 0.039). Taxonomic composition also differed: Oscillospirales was enriched in the clonidine-treated group, while a Prevotellaceae -dominant profile characterized the untreated continuous-light group. The authors' own conclusion is that sympathetic nerve inhibition restored the vital-sign and gut-microbiota changes caused by continuous light exposure.

Mechanism

Two distinct and untested-against-each-other mechanisms are on record, pointing in different directions. First, the protective one demonstrated in Zhao 2023: central sympathetic blockade prevented the stress-induced physiological disturbance (elevated blood pressure and heart rate) that plausibly drove the microbiota shift in untreated stressed animals, a gut-brain-axis route rather than a direct antimicrobial or intestinal effect. Second, an untested one: clonidine's own labeled reduction in gastrointestinal motility (mechanism screen category A, altered transit time), evidenced by the approximately 10% constipation rate and rare colonic pseudo-obstruction, is a well-established route by which slower colonic transit changes microbial fermentation and composition in general pharmacology, but no study has measured this specifically for clonidine.

Counter-evidence held on record

The constipating effect documented in clonidine's own label is a plausible route to a microbiome effect running in a direction this dossier cannot characterize, since no study has isolated it from the protective, stress-mediated finding above. Neither mechanism has been tested against the other in the same protocol. Do not present clonidine as protective of gut health in general; the one supporting study is a specific circadian-stress rescue model in rats, not a general finding, and it sits next to an entirely untested constipation-mediated mechanism that could point the other way. Do not present clonidine as harmful to gut bacteria either. No probiotic, fiber, or gut-health supplement recommendation follows from this entry, and none is made.

Limits on what this shows

• Key negative / null findings: The absence of any hemoglobin or hematocrit signal in the label, despite decades of post-marketing surveillance, is itself informative: drugs that meaningfully affect red cell mass tend to acquire a labeled laboratory-findings note over time, and clonidine's label carries no equivalent.
• At-risk subgroups: None defined. No population has been identified in which clonidine changes oxygen carriage or utilization.

Regulatory status

Hemoglobin, hematocrit, anemia, erythropoietin and red blood cell counts are not mentioned anywhere in the clonidine ER or Catapres labels reviewed for this dossier, confirmed again on direct review of the Warnings and Adverse Reactions sections on September 10, 2026. This is a genuine absence, not an oversight in the original review: unlike some antihypertensives, clonidine's label carries no hematologic laboratory findings subsection at all.

Population evidence

None on oxygen carriage, in humans or animals, at any tier. On oxygen utilization: Villa, Gorini and Ferrari, Neurochem Res 2022 (PMID 35099720, described in full under Mitochondrial burden above) measured cytochrome oxidase, the terminal, oxygen-consuming enzyme of the electron transport chain, alongside other energy-linked enzymes in three mitochondrial fractions of rat temporal cortex after a single acute clonidine dose. Cytochrome oxidase activity rose in the free- and light-mitochondria fractions and fell in the heavy-mitochondria fraction.

Mechanism

For carriage: none described or plausible. Clonidine has no documented effect on erythropoiesis, iron handling, or red cell survival at any tier reviewed for this dossier. For utilization: plausible but unresolved, the same compartment-specific energy-demand argument set out under mitochondrial burden. Clonidine's well-documented reduction in heart rate and cardiac output is its intended antihypertensive mechanism of action and is excluded here rather than treated as a nutrient-relevant oxygen-delivery finding; it is a hemodynamic effect of the drug working as designed, not evidence of a deficiency-driven or nutrient-mediated change in oxygen delivery.

Counter-evidence held on record

The label's silence on hemoglobin and hematocrit across every formulation reviewed (clonidine ER, Catapres, and the Health Canada monograph) is the strongest available evidence against a clinically relevant oxygen-carriage effect, though absence from a label is not the same as a study having looked and found nothing. Do not present clonidine as affecting oxygen delivery or utilization; the carriage side has no supporting data at all, the utilization side is one animal enzyme study with a mixed result, and the drug's well-known effect on heart rate and blood pressure is its intended action, not a nutrient-related finding. No iron, CoQ10, or other supplement recommendation follows from this entry.

Limits on what this shows

• Why no grade: The nearest available evidence is the energy-linked enzyme activity data from Villa 2022 (PMID 35099720), already graded under mitochondrial burden and, for the oxygen-consuming enzyme specifically, under oxygen delivery/utilization. Enzyme catalytic activity is a capacity measure, not a direct measurement of ATP output, and this dossier's governance rules hold that distinction deliberately so that one animal enzyme-activity study is not stretched to support three separate grades. With that data reserved for its own entries, no Tier B evidence remains that bears directly on ATP content, and no Tier C class-level ATP data for another alpha-2 agonist or imidazoline-receptor ligand was located either. White requires a circulating claim to rebut; the coenzyme Q10 claim already rebutted elsewhere in this dossier is the closest circulating claim in this general territory, but it names a specific nutrient rather than ATP output directly, and no separate "clonidine depletes cellular energy" or "clonidine lowers ATP" claim was located in the consumer sources already reviewed.
• What would fill it: A biochemical ATP assay or 31 P nuclear magnetic resonance measurement of high-energy phosphates in a defined clonidine-treated tissue, at a dose that maps to human therapy, with clonidine named as a study arm rather than pooled into a broader drug class.

What was searched

PubMed, September 10, 2026, clonidine combined with ATP, oxidative phosphorylation, and oxygen consumption; no clonidine-specific direct ATP or high-energy-phosphate assay was located in human or animal tissue.

Counter-evidence held on record

There is none to hold. Nothing supports an ATP-depletion claim for clonidine and nothing rules one out. Do not publish a claim that clonidine lowers or preserves cellular energy production; it has never been measured in a person or animal taking the drug at any tier that reaches ATP content directly.